Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hereditary angioedema News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A phase 3 trial demonstrates that oral deucrictibant effectively treats hereditary angioedema attacks on demand. This multicenter, randomized, double-blind study provides significant evidence for its potential use in clinical practice.

A study published in PubMed reveals that the c.1681-7 G>A variant in the Factor XII gene does not impact the splice site in a family diagnosed with hereditary angioedema due to Factor XII. This finding contributes to the understanding of genetic factors in this rare condition.

A recent study compares the management of hereditary angioedema in the UK with international guidelines, highlighting discrepancies in treatment approaches. This research could inform future policy and clinical practices in the management of this rare condition.

A recent study investigates the clinical impact of attack triggers in patients with hereditary angioedema. Understanding these triggers can enhance management strategies for this rare condition.

A recent study explores the hormonal and reproductive influences on disease activity in women with hereditary angioedema. This research highlights the need for tailored management strategies considering these factors.

A recent study evaluates deucrictibant as a potential treatment for hereditary angioedema, highlighting its therapeutic promise. The findings contribute to the ongoing research efforts aimed at improving management strategies for this rare condition.

A post-marketing surveillance study in Japan evaluates the real-world safety and effectiveness of icatibant in patients with hereditary angioedema. The findings contribute valuable insights into the drug's performance outside of clinical trials.

A narrative review highlights the long-term use of lanadelumab for prophylaxis in hereditary angioedema over the past seven years, consolidating clinical and real-world data. This analysis provides insights into the drug's effectiveness and safety profile in managing this rare condition.

A rare case study highlights the presentation and diagnosis of hereditary angioedema in a 7-year-old girl, emphasizing the need for improved management strategies. This case contributes to the understanding of hereditary angioedema and its clinical implications.

A recent study explores the use of berotralstat during pregnancy in a patient with hereditary angioedema. This research adds to the understanding of treatment safety in pregnant patients with this rare condition.

A recent study explores the social determinants of health in patients newly diagnosed with hereditary angioedema, highlighting their significant impact on healthcare resource utilization outcomes. Understanding these factors can inform better management strategies for this rare disease.

A study published in PubMed explores extending the dosing interval of lanadelumab for hereditary angioedema from every 2 weeks to every 4 weeks. This research could impact treatment regimens for patients managing this condition.

A new study analyzes heart rate variability in patients with hereditary angioedema due to C1 inhibitor deficiency using Holter monitoring. This research could enhance understanding of cardiovascular implications in this rare disease.

A case report highlights the relationship between hereditary angioedema and chronic spontaneous urticaria, providing insights into their co-occurrence. This study may inform future research and clinical approaches to managing these conditions.

A 4-year phase 2 open-label extension study demonstrates long-term efficacy and safety of donidalorsen for hereditary angioedema. The study provides valuable insights into the drug's sustained impact on patients over an extended period.

A recent international Delphi study identifies key barriers to on-demand treatment for hereditary angioedema attacks. The findings aim to inform strategies to improve patient access and management of this rare condition.

Recent research emphasizes the need to rethink management strategies for hereditary angioedema. The study highlights potential new approaches that could improve patient outcomes.

A multinational survey highlights the significant burden of hereditary angioedema on caregivers of both adult and pediatric patients. The findings underscore the need for improved support and resources for families affected by this rare condition.

BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal to enhance its portfolio with a long-acting preventive therapy for hereditary angioedema. This acquisition reflects a strategic shift in venture firms' preferences as the biotech sector recovers.

A study published in PubMed highlights the patient experience of hereditary angioedema, focusing on a racially diverse sample of adult patients. The findings aim to enhance understanding of the condition's impact on different demographics.

Not rare diseases news,news about your rare disease.